Literature DB >> 15576415

Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis.

J J Haringman1, D M Gerlag, A H Zwinderman, T J M Smeets, M C Kraan, D Baeten, I B McInnes, B Bresnihan, P P Tak.   

Abstract

BACKGROUND: Previous work identified synovial sublining macrophage numbers as a potential biomarker for clinical efficacy in rheumatoid arthritis.
OBJECTIVE: To investigate the association between changes in infiltration of synovial macrophages and clinical improvement after antirheumatic treatment.
METHODS: 88 patients who participated in various clinical trials were studied. All patients underwent serial arthroscopy before initiation of treatment and after different time intervals. Immunohistochemical and digital image analysis were performed according to standardised procedures to detect changes in CD68+ synovial sublining macrophages in relationship to changes in the 28 joint count Disease Activity Score (DAS28). Statistical analysis was performed using one way analysis of variance, the independent samples t test, linear regression, and the standardised response mean (SRM).
RESULTS: For good, moderate, and non-responders, according to the DAS28 response criteria, there was a significant difference in the change in sublining macrophages (mean (SEM) cells/mm(2) -643 (124), -270 (64), and -95 (60), respectively; p<0.0003). There was a significant correlation between the change in the number of macrophages and the change in DAS28 (Pearson correlation 0.874, p<0.01). The change in sublining macrophages explained 76% of the variation in the change in DAS28 (p<0.02). The sensitivity to change of the biomarker was high in patients treated actively (SRM >0.8), whereas the ability to detect changes in placebo treated patients was weak (SRM <0.3).
CONCLUSION: The results suggest that changes in synovial sublining macrophages can be used to predict possible efficacy of antirheumatic treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576415      PMCID: PMC1755544          DOI: 10.1136/ard.2004.029751

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  29 in total

Review 1.  Synovial biopsy in arthritis research: five years of concerted European collaboration.

Authors:  B Bresnihan; P P Tak; P Emery; L Klareskog; F Breedveld
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

Review 2.  Targeting interleukin-1 in the treatment of rheumatoid arthritis.

Authors:  Jean-Michel Dayer; Barry Bresnihan
Journal:  Arthritis Rheum       Date:  2002-03

3.  The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis.

Authors:  G Cunnane; A Madigan; E Murphy; O FitzGerald; B Bresnihan
Journal:  Rheumatology (Oxford)       Date:  2001-01       Impact factor: 7.580

4.  Treatment-induced remission in rheumatoid arthritis patients is characterized by a reduction in macrophage content of synovial biopsies.

Authors:  M D Smith; M C Kraan; J Slavotinek; V Au; H Weedon; A Parker; M Coleman; P J Roberts-Thomson; M J Ahern
Journal:  Rheumatology (Oxford)       Date:  2001-04       Impact factor: 7.580

5.  Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.

Authors:  P C Taylor; A M Peters; E Paleolog; P T Chapman; M J Elliott; R McCloskey; M Feldmann; R N Maini
Journal:  Arthritis Rheum       Date:  2000-01

Review 6.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Authors:  M Feldmann; R N Maini
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

7.  Quantification of the cell infiltrate in synovial tissue by digital image analysis.

Authors:  M C Kraan; J J Haringman; M J Ahern; F C Breedveld; M D Smith; P P Tak
Journal:  Rheumatology (Oxford)       Date:  2000-01       Impact factor: 7.580

8.  Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.

Authors:  M C Kraan; R J Reece; E C Barg; T J Smeets; J Farnell; R Rosenburg; D J Veale; F C Breedveld; P Emery; P P Tak
Journal:  Arthritis Rheum       Date:  2000-08

9.  Association of clinical, radiological and synovial immunopathological responses to anti-rheumatic treatment in rheumatoid arthritis.

Authors:  A R Pettit; H Weedon; M Ahern; S Zehntner; I H Frazer; J Slavotinek; V Au; M D Smith; R Thomas
Journal:  Rheumatology (Oxford)       Date:  2001-11       Impact factor: 7.580

Review 10.  Macrophages in rheumatoid arthritis.

Authors:  R W Kinne; R Bräuer; B Stuhlmüller; E Palombo-Kinne; G R Burmester
Journal:  Arthritis Res       Date:  2000-04-12
View more
  158 in total

1.  Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids.

Authors:  Z N Jahangier; J W G Jacobs; M C Kraan; M J G Wenting; T J Smeets; J W J Bijlsma; F P J G Lafeber; P P Tak
Journal:  Ann Rheum Dis       Date:  2006-04-20       Impact factor: 19.103

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

3.  The needle and the damage done.

Authors:  J K Franz; G-R Burmester
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

Review 4.  Standardisation of synovial tissue infiltrate analysis: how far have we come? How much further do we need to go?

Authors:  M D Smith; D Baeten; A-K Ulfgren; I B McInnes; O Fitzgerald; B Bresnihan; P P Tak; D Veale
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

Review 5.  Pathogenesis of spondyloarthritis: insights from synovial membrane studies.

Authors:  Leen De Rycke; Elli Kruithof; Bernard Vandooren; Paul P Tak; Dominique Baeten
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

6.  Activin A: a potential therapeutic target for characterizing and stopping joint pain early in rheumatoid arthritis patients.

Authors:  Fei Dong; Xijing He
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

7.  Transcription factor NFAT5 promotes macrophage survival in rheumatoid arthritis.

Authors:  Susanna Choi; Sungyong You; Donghyun Kim; Soo Youn Choi; H Moo Kwon; Hyun-Sook Kim; Daehee Hwang; Yune-Jung Park; Chul-Soo Cho; Wan-Uk Kim
Journal:  J Clin Invest       Date:  2017-02-13       Impact factor: 14.808

8.  Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis.

Authors:  D Baeten; J Houbiers; E Kruithof; B Vandooren; F Van den Bosch; A M Boots; E M Veys; A M M Miltenburg; F De Keyser
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

Review 9.  Inflammatory osteolysis: a conspiracy against bone.

Authors:  Gabriel Mbalaviele; Deborah V Novack; Georg Schett; Steven L Teitelbaum
Journal:  J Clin Invest       Date:  2017-06-01       Impact factor: 14.808

10.  Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.

Authors:  Jamie Campbell; Josquin Nys; Laura Eghobamien; E Suzanne Cohen; Matthew J Robinson; Matthew A Sleeman
Journal:  MAbs       Date:  2016-08-12       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.